Brutalist Biotech
Max
3
|
5
|
10
|
20
items per feed.
Cutting-edge Biotech news: Presented the old-fashioned way.
Fierce Biotech
Merck’s MASH hopeful efinopegdutide wins in mid-stage study
(9h)
‘Cancer hasn't seen this molecule before’: Onchilles’ injection shows potential for solid tumors
(11h)
J&J-backed Delix drums up $100M series C for non-hallucinatory psychedelic for depression
(14h)
AHA: Boehringer aims for 2027 survodutide submission after obesity drug passes cardio test
(15h)
Spruce spins out preclinical endocrinology program into newly formed Adrenyx
(15h)
Zura scraps hidradenitis suppurativa program after phase 2 miss, sinking stock
(16h)
Sanofi-backed Windward breezes toward $204M IPO to fund respiratory pipeline from China
(16h)
Advanced Analytics Help Reduce Control Animal Use While Preserving Scientific Rigor
(17h)
When China Fits a Global Clinical Development Strategy
(17h)
Kyorin pens $140M deal for Japan rights to Edesa’s phase 3 respiratory drug
(17h)
BioPharma Dive
BIO unveils plan for US to remain biotech’s ‘global leader’
(1h)
Bayer wins FDA nod for a new kind of blood thinner
(7h)
Vir hepatitis D drug succeeds in first pivotal study
(13h)
Argenx to buy peptide platform in potentially billion-dollar deal
(13h)
Ramaswamy’s biotech baggage haunted his political run
(14h)
State incentives for commercial-stage life sciences companies
(20h)
Translating Phase II success into Phase III readiness takes more than scale
(20h)
Making the ‘impossible’ executable in life sciences construction
(20h)
Novartis reveals cancer cases possibly linked to gene therapy Zolgensma
(3d)
Lilly, Hims reach GLP-1 deal; Alnylam sales chief to step down
(3d)
Endpoints News
Bayer wins FDA approval for stroke prevention drug Sunharbo
(6h)
How early efforts to build autonomous clinical AI tools are approaching regulation
(9h)
Trump’s drug pricing deals force tough choices on launches
(10h)
FDA orders GLP-1 drugmakers to warn of rare eye disease
(10h)
US government removes WuXi AppTec from Chinese military list
(11h)
Third Rock enters $2B partnership with AI-focused Chinese biotech
(11h)
Heron sells assets to CorMedix for $145M upfront; Faeth's stock tumbles
(14h)
Neuroplastogen biotech Delix raises $100M Series C
(14h)
#AHA26: Boehringer to seek approval of obesity shot, but gaining market share could be tricky
(14h)
#AHA26: Lilly gets another sleep apnea win, this time with obesity pill
(15h)
BioSpace
BioSpace 2027 Best Places to Work shines light on most admired employers
(1h)
FDA orders class-wide GLP-1 label update to include potential risk for rare eye disease
(11h)
Boehringer, Zealand’s obesity drug doesn’t elevate heart risk in key late-stage test
(11h)
Lilly to seek second sleep apnea approval after Foundayo reduces disease severity in Phase 3
(12h)
Vir's hepatitis delta combo tamps down virus as Gilead showdown looms
(12h)
J&J and Protagonist’s Icotyde improves psoriatic arthritis but AbbVie’s Skyrizi likely to reign
(14h)
Details from Novartis’ failed cardiovascular trial offer ‘little silver lining’ for rivals
(14h)
Argenx buyout of peptide engine and Big Pharma favorite UNP could top $1B
(15h)
Novo’s troubled cardio drug could find niche in less sick patients
(16h)
With an approval apiece, the verdict is still out on AbbVie’s and BMS’ twin neuro buys
(1d)
STAT News
Ionis Pharmaceuticals shares plummet after slow rollout of biotech’s triglyceride-lowering drug
(5h)
FDA approves novel Bayer drug to reduce recurrence of stroke
(7h)
Trump administration removes WuXi AppTec from its Chinese military list
(9h)
Bill Ackman’s bold plan to transform brain research
(11h)
Hospitals win the midterms, and Chopping Very Strategically
(12h)
Heart association meeting’s readout is trending ‘neutral’
(13h)
FDA warns GLP-1 drugs carry potential risk of rare eye condition
(14h)
Gene therapy’s long-debated cancer risk materializes
(15h)
Eli Lilly’s GLP-1 pill Foundayo helped alleviate sleep apnea in studies
(15h)
We’re reading about a Novartis heart drug, BIO fighting a Trump program, and more
(15h)
BioPharma Trend
The Biobank Bet: Why AI’s Next Frontier Is Stored Human Biology — A Conversation with Maccabi’s Michal Zucman-Katz
(10h)
The $1.8 Billion Bet That More Data Will Enable Progress in Virtual Cells
(5d)
The Virtual Cell Tracker: Who’s Building Them, What Works, Where the Money Goes
(5d)
Anthropic Files for IPO: S-1 Shows 9 of the 10 Largest Pharma Companies in the Fortune 500 Are Paying Customers
(2w)
Benchling’s Science Foundries put teams of AI agents in charge of whole R&D workflows
(4w)
When Agents Run Computations: Schrödinger’s Robert Abel On Where The Human Still Decides
(1mo)
WhiteLab Genomics Raises $26M to Scale AI-designed Delivery Systems for Cell and Gene Therapies
(1mo)
The $2.7B Question: How Do We Know If Isomorphic's AI Works?
(1mo)
Biotech IPOs Roar Back, With Nvidia-Backed Iambic Next in Line
(1mo)
AI Drug Discovery Startups Raise $526 Million in Two Days
(1mo)
Drug Channels
BlinkRx Insights: Clarifying the Mystery around “DTP”
(3d)
Disintegration: Adam’s Four Takeaways from the CVS Health Breakup
(4d)
Drug Channels Outlook 2027: Adam’s Final Webinar
(6d)
Biopharma’s AI Fork in the Road
(1w)
"How Do I Know I'm Not Just Giving Money Away?" The Question Every Market Access Leader Is Asking
(1w)
Drug Channels News Roundup, October 2026: Part D’s Hidden Cost Sharing Gap, 340B’s $244 Billion Footprint, The Net Price Rebate Model, Cigna’s Wholesale Push, and Four Ways to Bag a Drug
(2w)
Copay + GTN Revenue Protection = Better Together
(2w)
Alternative PBM Satisfaction Declined in 2026, Shrinking the Advantage Over the Big Three PBMs
(3w)
Informa's Trade and Channel Strategies
(3w)
10 Crucial Trends Facing U.S. Drug Wholesalers in 2026 and Beyond
(4w)
European Biotechnology Magazine
Immunocore doubles up on T-cell engagers in eye cancer
(13h)
argenx buys macrocycle partner Unnatural Products for up to $1.15 billion
(22h)
CDMO: How to find a reliable partner
(1d)
When genetic medicine enters the inner ear
(1d)
Turn bioprocess data into timely, transferable process control
(3d)
Spinal muscular atrophy: Tumors reported following Novartis gene therapy
(3d)
Oculis taps Roche veteran after setback; ARTHEx brings in Azafaros’ CMO; CRISPR recruits Orna’s former CTO
(3d)
Dutch biotech Anaheim launches with €40M to develop pseudogout treatment
(3d)
Boehringer secures six Chinese cancer programs in deal worth up to $7B
(4d)
BioNTech: BMS becomes a revenue mainstay — but the pipeline still has to deliver
(4d)
Drug Hunter
Thinking Outside of the Taxonomic Box: Non-Traditional In Vivo Species in Drug Discovery
(14h)
Lenacapavir, a First-in-Class HIV Capsid Inhibitor for the Treatment and Prevention of HIV-1 Infection
(15h)
Chronic CRFR2 Agonism for Muscle-Sparing Weight Loss
(3d)
RG6182
(4d)
A Deep Dive into INN Proposed List 135 Part 2 (M–Z)
(5d)
A Deep Dive into INN Proposed List 135 Part 1 (A–L)
(6d)
Two Fluorines, One Carbon, Many Possibilities
(1w)
September 2026 Patent Gazette
(1w)
September 2026
(2w)
pamiparib
(2w)
Labiotech.EU
Zooming out from ovaries: how has renaming PMOS changed lives?
(3d)
How to turn a BIO-Europe meeting into a lasting partnership
(3d)
From gene editing to RNA therapies: The biotech trends to look out for at AHA Scientific Sessions 2026
(5d)
The biggest biotech funding rounds in October 2026
(5d)
Top biotech deals in October 2026
(6d)
Why global expansion is changing the shape of the ATMP supply chain
(6d)
Teva’s pipeline in 2027: Can it sustain its transformation?
(1w)
ESMO 2026: readouts and highlights at the oncology summit
(1w)
Genprex bets on a one-time gene therapy for diabetes (Part 3 of 3)
(1w)
New idiopathic pulmonary fibrosis drugs on the way
(2w)
Bio IT World
NCOA7 Emerges as Drug Target Linking Pulmonary Hypertension to Brain Inflammation
(23m)
Fresenius WuXi Biologics Partner, Pfizer Deploys Edison's AI Scientist, Ultima, Illumina Win Singapore National Sequencing Award
(3d)
Gxp Compliance Support Is Coming To The Public Cloud. That’s Good For Life Sciences
(5d)
Quantifying the Average Human Genome
(1w)
Regulatory Affairs Is the Connective Tissue Pharma’s AI Strategy Is Missing
(2w)
Follow the Money: OMass Raises Series C, Pathos AI Drug Development, Owkin Alums Launch Rivercell
(2w)
ParkourSC Acquires Quartic, PacBio Partners with Verily, CAS Data Arrives in Microsoft Copilot
(2w)
Innovating at Speed in an Underrated Drug-Making Process
(3w)
Inside the ‘Public Library of Blueprints’: How the ASAP Discovery Consortium Turned Open Science Into an Antiviral Pipeline
(3w)
New Pipeline Reveals RNA Fusions Formed During Inflammation, Opens New Frontier in Biology
(3w)
GEN News
Illumina Offers Early Access to Duplex Sequencing for MRD, Tumor Evolution Research
(6h)
How Cancer-Associated Gene Triggers Cell Division Without Unpacking the Genome
(9h)
Childhood Cancers May Not Always Need Extra Mutations to Spread, Study Suggests
(16h)
New AI Models Are Turbo-Charging Protein Design
(16h)
Therapeutic Immune Manipulation
(16h)
Formulation Development Roundup
(16h)
StockWatch: Nurix Nosedives as Sanofi Halts Phase I Immunology Candidate
(1d)
The Aging Proteome: Clocks, Cohorts, and Clinical Trials
(3d)
Novartis Confirms Nine Cases of Tumors in Children Treated with Gene Therapy Zolgensma
(3d)
ER-Negative Breast Cancer Risk Linked with Blood Levels of Two PFAS Forever Chemicals
(3d)
Cure Today
Glioblastoma Patients Can Request Genomic Testing on Their Tumor Tissue
(8h)
Weight Loss With Pancreatic Cancer: Why It Happens and What Helps
(10h)
Rural Lung Cancer: Only 36% of Medicare Patients Had Gene Testing
(14h)
Datroway Slows Brain Metastases in Triple-Negative Breast Cancer
(16h)
Nearly Half of Cancer Survivors Report Recent Alcohol Use
(2d)
Hot Flash Drug Works at Any Point in Breast Cancer Hormone Therapy
(2d)
Glioblastoma Genomic Testing: What Patients Should Ask
(3d)
How Patients With Breast Cancer Can Catch Lymphedema Before Swelling Starts
(3d)
Survivor Guilt After a Double Mastectomy for DCIS Breast Cancer
(3d)
FDA Approves Rybrevant Faspro for Advanced Head and Neck Cancer
(3d)
Contract Pharma
Spruce Bio Spins CAH Program Off into New Subsidiary Adrenyx
(8h)
Pluri CDMO Business Adds Two ISO Certifications
(14h)
Charles River to Acquire Frontage’s Bioanalysis, DPMK Businesses
(15h)
Pierre Fabre, XtalPi Partner to Advance AI-Driven Drug Discovery
(15h)
Centrix Appoints Nathalie Huther as SVP, Business Development & Commercial
(16h)
Hovione Discusses Spray Drying Expansions in US and Europe
(3d)
Chai Discovery, Roche to Collaborate on AI Drug Discovery
(3d)
Can AI Solve Pharmacovigilance’s Evidence Bottleneck?
(3d)
FDA Approves J&J’s Rybrevant Faspro with Halozyme’s Enhanze for Head and Neck Cancer
(3d)
Lotte Biologics CEO on Alvotech Deal, Manufacturing Expansion and Building a New CDMO Model
(3d)
Pharma Times
Japan approves prefilled syringe for GSK’s shingles vaccine
(1mo)
EpilepsyGTx and Viralgen partner to scale AAV manufacturing for EPY201
(1mo)
Zerion partner files first EU application for Dispersome‑enabled product
(1mo)
Tozorakimab shows broad COPD benefit in new phase 3 data
(1mo)
Study highlights advance in influenza protection for older adults
(1mo)
NICE backs daratumumab quadruplet for transplant‑eligible myeloma
(1mo)
Teitur reports positive early data for Parkinson’s peptide TT‑P34
(1mo)
Amivantamab regimen delivers longest survival in EGFR Ex20ins lung cancer
(1mo)
NICE backs ibrutinib regimen for untreated mantle cell lymphoma
(2mo)
Livdelzi accepted in Scotland for treatment of PBC
(2mo)
Medcity News
Startup Supporting Caregivers Raises $3.5M in Seed Funding
(6h)
Digital Health’s GLP-1 Strategy: “You Didn’t Come for the Drug. You Came for Health”
(8h)
Argenx Adds Oral Peptides to Its Immunology Strategy With $550M UNP Acquisition
(8h)
Simulation-Guided Clinical Trials: Is EU Law Ready?
(15h)
Nkarta Autoimmune Disease Cell Therapy’s First Human Data Show Safety, Signs of Efficacy
(18h)
What’s Driving the Consumerization of Healthcare?
(1d)
Missing the Point: Isolation Alone Will Not Build AI Safety
(1d)
Bispecific J&J Drug Wins Speedy FDA Approval for Treating Head & Neck Cancer
(3d)
Experian Health Survey: Providers Struggle Amid Increasing Claim Denials
(3d)
The Big Challenge for AI in Healthcare Comes After Approval
(3d)
Chemical & Engineering News
Comment: To NOBCChE, community is everything
(5h)
Chemistry in Pictures: Golden tears
(10h)
Mitsui Chemicals will acquire JSR in electronic materials push
(11h)
Purple bacteria transform waste into valuable antioxidant
(13h)
ACS expands public policy fellowships
(14h)
Comment: Creating pathways to success through Project SEED
(16h)
Uncovered: Plastic pyrolysis
(17h)
C&EN Chemwords, Nov. 9
(17h)
‘Journal of Physical Chemistry Letters’ names next editor in chief
(3d)
Using old wind turbine blades to make new ones
(3d)
The Pharma Letter
Pierre Fabre and XtalPi ink discovery AI-driven collaboration
(13h)
Adneuris files cebranopadol NDA for acute pain, pitching lower abuse potential than oxycodone
(13h)
Almirall nine-month sales up 8.3% as Ebglyss surges 75% and EBITDA climbs 22.7%
(16h)
Russia to sharply increase production of human papillomavirus vaccines
(16h)
Avanzanite builds EU commercial operation by securing Zemcelpro rights
(17h)
Pelacarsen cuts Lp(a) by 78% but not cardiovascular events in Phase III HORIZON trial
(17h)
Amgen’s Repatha lowers risk of heart attacks by 20%
(18h)
Amgen’s Repatha lowers risk of heart attacks by 20%
(18h)
SRTD Biotech raises a 31.5 million euros to develop mRNA therapeutics
(18h)
How hep C went from an $84,000 cure to mass treatment
(20h)
Targeted Oncology
Comparing Treatment Approaches in Second-Line Metastatic ccRCC
(8h)
Imneskibart Regimens Show Activity in ICI-Refractory Melanoma, NSCLC
(10h)
Dr Iyer on Digitizing NCCN Guidelines for AI at the Point of Care
(11h)
FDA Accepts sNDA for Gedatolisib in PIK3CA-Mutated HR+/HER2– Breast Cancer
(13h)
Benzopyran-Based Small Molecule Granted FDA Orphan Drug Status in AML
(14h)
Pembrolizumab Plus SBRT Fails to Improve EFS in Unresected Early-Stage NSCLC
(17h)
Dr Dasari on Emerging PRRT Options and New Therapeutic Targets in NETs
(1d)
NETs Year in Review: RLT Advances as Combo Strategies and ICIs Show Limited Benefit
(1d)
Real-World Data Reveal Risk Factors for Myeloid Neoplasm After Lutetium Lu 177 Dotatate
(1d)
Dr Chauhan on Oncolytic Virus SVV-001 Plus Ipi/Nivo in Neuroendocrine Cancers
(2d)
MedWatch
Ambu board seeks sharp increase in executive bonus caps
(17h)
Demant goes on offensive with US veterans: “We aim to steadily expand our position”
(17h)
Trustee to seek disqualification of former Audientes management
(19h)
Sandoz launches Ozempic copy in Brazil
(20h)
Wegovy improves liver markers in MASH patients without obesity
(21h)
Coloplast nominates Lundbeck CEO to its board
(21h)
Novo Nordisk releases real-world data on semaglutide in fatty liver disease
(22h)
Market turmoil threatens Leo Pharma’s planned IPO, Berlingske reports
(22h)
EU clears GN Hearing sale to Amplifon, bringing billion-krone payout closer
(3d)
Eli Lilly teams up with Hims & Hers on obesity drugs
(3d)
In The Pipeline
Jon Clardy, 1943-2026
(9h)
Antimicrobial Peptides for Fun (?) and Profit (?)
(4d)
The Morning After the Midterms
(5d)
Taming Photochemistry
(6d)
Chemotherapy Actually Helps Immunotherapy in Cancer
(1w)
Messing Around With the Warburg Effect
(2w)
Lipidation and Its Discontents
(2w)
What Does It Mean to "Know Medicinal Chemistry"?
(2w)
The Merck/Moderna Results
(2w)
Elevenostat: Don't Believe the Label
(3w)
Pharmaphorum
Amazon puts $100m into global health drive
(16h)
MHRA grants Innovation Passports to three novel drugs
(17h)
argenx agrees Unnatural takeover deal worth up to $1.15bn
(18h)
Moderna to relocate its UK HQ to London's Tribeca
(19h)
Novartis' pelacarsen fail raises questions for other drugs
(20h)
Lilly partners with Hims & Hers on obesity drug sales
(3d)
Inflammation-focused Rezera sets terms for IPO
(3d)
Moderna, Oxford Uni Ebola jabs backed for pivotal testing
(3d)
UK pilots shorter NICE appraisal for new medicines
(3d)
J&J's Rybrevant moves beyond lung cancer with new approval
(3d)
Drug Discovery Weekly
UQ technology opens new front in Alzheimer’s and Parkinson’s
(1w)
Why we need to rethink childhood cancer treatments
(1w)
Q3 UK biotech VC heads for record year thanks to megadeals
(1w)
Measuring what matters: Applying ultrasensitive immunoassays for clinical biomarkers
(1w)
New webinar: Applying ultrasensitive immunoassays for clinical biomarkers
(2w)
Partnership advances AI-driven R&D collaboration
(2w)
The three generations of obesity medicines
(2w)
Webinar: Exploring warm PDX benefits and onsite expertise
(2w)
Beyond the model: Exploring warm PDX benefits and onsite expertise
(2w)
ScionxBio collaborates to develop long-acting xRNA therapeutics
(2w)
HIT Consultant
AWS Launches $100M Health Impact Initiative to Scale Agentic and Cloud Tech in Underserved Global Care
(13h)
M&A: XRHealth Acquires PursueCare to Bridge Immersive VR Therapy with FDA-Authorized Prescription Digital Therapeutics
(14h)
Reclaiming $44.9B in Hospital Uncompensated Care via Automated Upfront Eligibility
(15h)
CLEAR Launches Epic Toolbox Integrations for EpicCare Link and DEA-Compliant EPCS
(16h)
SEARHC Joins Mayo Clinic Care Network to Bridge Specialist Tele-Informatics Across Southeast Alaska
(16h)
GDIT, IHS, and Oracle Health Deploy PATH EHR as the First Cloud-Native Federal Health System
(16h)
Why Patient Access Is Healthcare’s Highest-Leverage Growth Lever
(1d)
Do Patients Need to Understand AI Before They Can Trust It?
(3d)
M&A: Ellipsis Health Acquires Kouper Health to Unify Vocal Empathy with Native EHR Navigation
(3d)
FinThrive Appoints Ex-Optum Executive Sam Meckey as CEO to Accelerate End-to-End RCM AI Orchestration
(3d)
Insights: Pink Sheet
US FDA Defines Risk-Based Potency Approach To Cell and Gene Therapy
(2h)
Korea Streamlines Review Of Digital Convergence Combos
(3h)
US FDA Probes Tumor Risk With Novartis’ Zolgensma And Itvisma After Gene Integration Reports
(5h)
GLP-1 Class Warning On Rare Eye Condition Driven By US FDA Meta-Analysis, Sentinel Study
(6h)
EU Risks ‘Completely Screwing Up’ Pharma Sandboxes, Academic Warns
(16h)
Recruitment To Industry Trials Falls For Fifth Year In UK Despite Faster Approvals
(16h)
Ad/Promo: Multiple US FDA Advisory Comment Requests OK, But Know Their Limits
(3d)
CMS Retains ‘Value Of 12’ For One-Time Therapies In Medicare Negotiation Despite Pushback
(3d)
US FDA Biologics Center Joins Hiring Binge, Posts First Net Gain Since Pre-Trump Administration
(3d)
Pink Sheet Podcast: How Will FDA And Rx Industry Navigate Aftermath Of Midterm’s Blue Wave?
(3d)
BioXconomy
Optimizing the Affordability Journey: Insights from a Real-World Brand Case Study
(2d)
Standardization, not customization: A site-CRO perspective on trial quality
(8h)
Survey finds women are willing to join trials, yet rarely invited
(11h)
Argenx buys into macrocyclic peptides with $1.15bn UNP deal
(15h)
Pharma urged to build pricing resilience
(15h)
Small patients, big breakthrough: Using peptides to treat hypoxic brain injuries in preterm babies
(17h)
Medicare Part D premiums, caps climb in 2027 plans
(3d)
Novartis under scrutiny as nine tumor cases reported in Zolgensma SMA patients
(3d)
Indian CDMO Shilpa commits to $50M expansion in peptide manufacturing
(3d)
When speed to market outpaces readiness to lead
(3d)
BioCentury
China’s first-in-class deals grow as U.S. investment curbs loom — a BioCentury podcast
(3d)
Post-election pricing outlook: stormy with a chance of compromise
(3d)
Rezera proposes IPO terms amid volatile NASDAQ conditions: Public Equity Report
(3d)
Brinsupri, Rasonque extend biotech's launch momentum
(3d)
SITC 2026: Engineering immune responses inside tumors
(4d)
With $600M fund, Formation Bio puts a financing twist on hub-and-spoke model
(4d)
Alethio: A mutation-agnostic approach to essential thrombocythemia
(4d)
Nisa Leung’s Aulis Capital closes $200M debut fund: Venture Report
(4d)
Innovation Radar: New clues to targeting Alzheimer’s microglia
(5d)
Building biology’s missing datasets to train AI models
(5d)
SCRIP
Cultivating An iPSC Ecosystem: RACTHERA CEO On Japan Cell Therapy Journey
(1h)
Novartis’s Detailed Pelacarsen Data Leave Little Hope For Other Lp(a)-Lowering Drugs
(7h)
ACR 2026: A Tale Of Three Cell Therapies
(8h)
Argenx Buys Unnatural Products, Gaining Macrocyclic Peptide Discovery Platform
(8h)
BIO-Europe: Wise Words From Industry Vets Levin And Moses
(14h)
J&J’s Prostate Cancer Combo Shows Promise, As Phase III Proceeds
(16h)
Scrip’s Five Must-Know Things: Madrigal’s MASH Whistleblower, Lilly, Sanofi Hunt Deals
(1d)
AASLD 2026: Madrigal Plans New Phase III Study In Cirrhotic MASH
(3d)
Market Snapshot: After Mimrylo, What’s Next For Myeloproliferative Neoplasms?
(3d)
J&J’s Rybrevant Faspro Should See Few Challenges In Head And Neck Uptake
(3d)